医学
放射科
血管侵犯
切除术
外科
克拉茨金瘤
外科切除术
梅德林
总体生存率
存活率
肿瘤分期
作者
Takashi Mizuno,Tomoki Ebata,Yukihiro Yokoyama,Tsuyoshi Igami,Junpei Yamaguchi,Shunsuke Onoe,Nobuyuki Watanabe,Yuzuru Kamei,Masato Nagino
出处
期刊:Annals of Surgery
[Lippincott Williams & Wilkins]
日期:2020-09-24
卷期号:275 (2): 382-390
被引量:100
标识
DOI:10.1097/sla.0000000000004322
摘要
OBJECTIVE: To evaluate the efficacy and safety of combined vascular resection (VR) in advanced perihilar cholangiocarcinoma (PHC). SUMMARY OF BACKGROUND DATA: Hepatectomy combined with portal vein resection (PVR) and/or hepatic artery resection (HAR) is technically demanding but an option only for tumor eradication against PHC involving the hilar hepatic inflow vessels; however, its efficacy and safety have not been well evaluated. METHODS: Patients diagnosed with PHC during 2001-2018 were included. Patients who underwent resection were divided according to combined VR. Patients undergoing VR were subdivided according to type of VR. Postoperative outcomes and OS were compared between patient groups. RESULTS: Among the 1055 consecutive patients, 787 (75%) underwent resection (without VR: n = 484, PVR: n = 157, HAR: n = 146). The incidences of postoperative complications and mortality were 49% (without VR vs with VR, 48% vs 50%; P= 0.715) and 2.1% (without VR vs with VR, 1.2% vs 3.6%; P= 0.040), respectively. The OS of patients who underwent resection with VR (median, 30 months) was shorter than that of those who underwent resection without VR (median, 61 months; P < 0.0001); however, it was longer than that of those who did not undergo resection (median, 10 months; P < 0.0001). OS was not significantly different between those who underwent PVR and those who underwent HAR (median, 29 months vs 34 months; P = 0.517). CONCLUSION: VR salvages a large number of patients from having locally advanced PHC that is otherwise unresectable and is recommended if the hilar hepatic inflow vessels are reconstructable, providing acceptable surgical outcomes and substantial survival benefits.
科研通智能强力驱动
Strongly Powered by AbleSci AI